search
Back to results

Microembolic Signals During CPVI (Circumferntial Pulmonary Vein Isolation) Assessed by TCD (Trans-cranial Doppler)

Primary Purpose

Atrial Fibrillation.

Status
Completed
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
TCD monitoring of microembolic signal during procedure
Sponsored by
Tel-Aviv Sourasky Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Atrial Fibrillation. focused on measuring Atrial fibrillation, CPVI, TCD, nMARQ, MES, microembolic signals

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 20 patients undergoing pulmonary vein isolation (PVI) for highly symptomatic, drug refractory paroxysmal or persistent AF.
  • Above 18 years of age
  • Following the signing of informed consent

Exclusion Criteria:

  • Special populations
  • Chronic Atrial fibrillation

Sites / Locations

  • Tel Aviv Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

conventional irrigated ablation catheter

nMARQ circumferential irrigated catheter

Arm Description

TCD testing during procedure from trans-septal puncture until completion using a conventional irrigated ablation catheter. Intervention: TCD monitoring of microembolic signal during procedure

TCD testing during procedure from trans-septal puncture until completion using the nMARQ circumferential irrigated catheter. Intervention: TCD monitoring of microembolic signal during procedure

Outcomes

Primary Outcome Measures

Number of microembolic signals during CPVI

Secondary Outcome Measures

Full Information

First Posted
March 6, 2014
Last Updated
July 6, 2016
Sponsor
Tel-Aviv Sourasky Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT02082366
Brief Title
Microembolic Signals During CPVI (Circumferntial Pulmonary Vein Isolation) Assessed by TCD (Trans-cranial Doppler)
Official Title
Microembolic Signals During CPVI (Circumferntial Pulmonary Vein Isolation) Assessed by TCD (Trans-cranial Doppler)
Study Type
Interventional

2. Study Status

Record Verification Date
July 2016
Overall Recruitment Status
Completed
Study Start Date
March 2014 (undefined)
Primary Completion Date
January 2015 (Actual)
Study Completion Date
March 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Tel-Aviv Sourasky Medical Center

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of the investigators study is to analyze the incidence of MES by TCD performed during AF ablation with the nMARQ and to compare is with the incidence of MES using a conventional irrigated ablation catheter. Objective: To investigate the incidence of MES on TCD during AF ablation with the nMARQ catheter compared to a conventional irrigated ablation catheter. Following inclusion, patients will be randomized into 2 equal different treatment groups: PVI with traditional irrigated RF catheter versus PVI using the nMARQ catheter. In all patients, anticoagulation therapy with warfarin is discontinued five-days before the procedure and low molecular weight heparin is initiated at that time. A CT-scan of the left atrium is performed and imported into the Carto 3 mapping system. The ablation procedure is conducted under general anesthesia or conscious sedation. A decapolar catheter is positioned in the coronary sinus and a quadripolar catheter is positioned at the His bundle level through the right femoral vein. Two 8F sheaths are introduced into the left atrium with double trans-septal puncture performed under fluoroscopic, trans-esophageal echocardiographic or intracardiac echocardiography guidance. Upon completion of the first trans-septal puncture, intravenous heparin is administered to maintain an activated clotting time of 350 seconds throughout the procedure. A variable Lasso circular mapping catheter is introduced through the SL1 sheath into each pulmonary vein for electrical mapping. After the second trans-septal puncture, a Navistar Thermocool 3.5mm irrigated ablation catheter or an nMARQ circular irrigated ablation catheter are introduced into the left atrium. Of note, in case of use the nMARQ catheter, the second SL-1 sheath is replaced by a steerable 8F agilis sheath after the second trans-septal puncture. Each of the 4 PVs are imaged by selective angiograms. The left atrium geometry is created using the nMARQ catheter or the Navistar catheter and then merged with the pre-acquired CT scan of the left atrium and PVs. Identification of true MESs will be possible using an event detector system, in addition to determining whether the MESs are attributed to a solid or to a gaseous embolus. Total MES counts will be collected and evaluated separately during different stages of the procedure.
Detailed Description
Pulmonary vein isolation is increasingly been used to cure atrial fibrillation . A matter of concern comes from the evidence that AF ablation is associated by the appearance of microembolism on brain MRI scan. These microembolism are not associated with neurologic symptoms and seem to be at least partially, reversible in time. Correlation between the incidence of these cerebral lesions and the ablation technology used has been demonstrated: circular multipolar phased radiofrequency ablation using the PVAC catheter a duty-cycled non irrigated RF has been associated with the highest incidence of new lesion formation using MRI, whereas irrigated radiofrequency catheter and cryoablation seem to be the safer in this aspect. These thromboembolic events can be cumulatively assessed by the detection of microembolic signals in the cerebral arteries by transcranial Doppler performed during the ablation. Past studies have compared the incidence of MESs in TCD during PVI using different ablation techniques - Sauren et al. demonstrated that use of irrigated RF and or cryoablation produces significantly fewer cerebral MESs than the use of RF ablation with non irrigated catheters. A recent publication compared the occurrence of MESs using TCD while performing PVI by cryoablation compared with the PVAC catheter, reinforcing the MRI findings that the circumferential PVAC catheter possesses higher thromboembolic risk, possibly due to the lack of irrigation. Recently, a novel multipolar irrigated RF ablation catheter has been introduced. Ablations are performed simultaneously in a unipolar shape from 10 electrodes located at the tip of the ablation catheter. The catheter is under constant irrigation. No data exists regarding the incidence of MES in TCD during ablation with the nMARQ catheter. The aim of the investigators study is to analyze the incidence of MES by TCD performed during AF ablation with the nMARQ and to compare is with the incidence of MES using a conventional irrigated ablation catheter. Objective: To investigate the incidence of MES on TCD during AF ablation with the nMARQ catheter compared to a conventional irrigated ablation catheter. Methods: Study Population: 20 patients undergoing pulmonary vein isolation (PVI) for highly symptomatic, drug refractory paroxysmal or persistent AF. Study design: Following inclusion, patients will be randomized into 2 equal different treatment groups: PVI with traditional irrigated RF catheter versus PVI using the nMARQ catheter. In all patients, anticoagulation therapy with warfarin is discontinued five-days before the procedure and low molecular weight heparin is initiated at that time. A CT-scan of the left atrium is performed and imported into the Carto 3 mapping system. The ablation procedure is conducted under general anesthesia or conscious sedation. A decapolar catheter is positioned in the coronary sinus and a quadripolar catheter is positioned at the His bundle level through the right femoral vein. Two 8F sheaths are introduced into the left atrium with double trans-septal puncture performed under fluoroscopic, trans-esophageal echocardiographic or intracardiac echocardiography guidance. Upon completion of the first trans-septal puncture, intravenous heparin is administered to maintain an activated clotting time of 350 seconds throughout the procedure. A variable Lasso circular mapping catheter is introduced through the SL1 sheath into each pulmonary vein for electrical mapping. After the second trans-septal puncture, a Navistar Thermocool 3.5mm irrigated ablation catheter or an nMARQ circular irrigated ablation catheter are introduced into the left atrium. Of note, in case of use the nMARQ catheter, the second SL-1 sheath is replaced by a steerable 8F agilis sheath after the second trans-septal puncture. Each of the 4 PVs are imaged by selective angiograms. The left atrium geometry is created using the nMARQ catheter or the Navistar catheter and then merged with the pre-acquired CT scan of the left atrium and PVs. The PV antrum is defined with angiogram and electrograms analyses. Isolation of each PV is performed at the PV antrum by delivery of RF from multiple irrigated electrodes on the nMARQ catheter simultaneously and using the following settings: catheter irrigation flow rate of 60 mL/minute, target temperature 35 and maximal energy of 25 W for the anterior aspect of the antrum and 15W for the posterior atrial wall. RF energy is applied at each ablation site for a maximum of 45 seconds, until the local PV electrogram disappeared or its amplitude decreased by 80%. In case of RF ablation by the Navistar catheter, the ablation is performed in a "point by point" fashion at the PV antrum encircling the PV os. Ablation is performed with the following settings: catheter irrigation flow rate of 22 mL/minute, target temperature 35° and maximal energy of 35 W for the anterior aspect of the antrum and 20W for the posterior atrial wall. RF energy is applied at each ablation site for a maximum of 45 seconds, until the local PV electrogram disappeared or its amplitude decreased by 80%. Isolation of the left sided PVs is conducted during atrial pacing from the distal CS catheter whereas isolation of the right PVs is conducted during sinus rhythm. The endpoint of the procedure is the isolation of all PVs, attested by disappearance of all PV potentials in the lasso catheter within the vein and confirmed by pacing maneuvers. TCD recording will be performed throughout the whole period of the PVI procedure from the preparation of trans-septal LA access until the termination of the procedure. The transducer is held in place by a proprietary headpiece supplied with the system. The middle cerebral arteries will be bilaterally insonated from transtemporal windows by using a multifrequency Doppler. Identification of true MESs will be possible using an event detector system, in addition to determining whether the MESs are attributed to a solid or to a gaseous embolus. Total MES counts will be collected and evaluated separately during different stages of the procedure. All statistical analysis and manuscript drafting will be performed at the Tel Aviv medical center.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation.
Keywords
Atrial fibrillation, CPVI, TCD, nMARQ, MES, microembolic signals

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
conventional irrigated ablation catheter
Arm Type
Active Comparator
Arm Description
TCD testing during procedure from trans-septal puncture until completion using a conventional irrigated ablation catheter. Intervention: TCD monitoring of microembolic signal during procedure
Arm Title
nMARQ circumferential irrigated catheter
Arm Type
Active Comparator
Arm Description
TCD testing during procedure from trans-septal puncture until completion using the nMARQ circumferential irrigated catheter. Intervention: TCD monitoring of microembolic signal during procedure
Intervention Type
Device
Intervention Name(s)
TCD monitoring of microembolic signal during procedure
Intervention Description
monitoring of microembolic signal during procedure
Primary Outcome Measure Information:
Title
Number of microembolic signals during CPVI
Time Frame
During procedure - 4 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 20 patients undergoing pulmonary vein isolation (PVI) for highly symptomatic, drug refractory paroxysmal or persistent AF. Above 18 years of age Following the signing of informed consent Exclusion Criteria: Special populations Chronic Atrial fibrillation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rephael Rosso, MD
Organizational Affiliation
Tel Aviv Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Tel Aviv Medical Center
City
Tel Aviv
Country
Israel

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Microembolic Signals During CPVI (Circumferntial Pulmonary Vein Isolation) Assessed by TCD (Trans-cranial Doppler)

We'll reach out to this number within 24 hrs